CA3073794A1 - Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family - Google Patents

Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family Download PDF

Info

Publication number
CA3073794A1
CA3073794A1 CA3073794A CA3073794A CA3073794A1 CA 3073794 A1 CA3073794 A1 CA 3073794A1 CA 3073794 A CA3073794 A CA 3073794A CA 3073794 A CA3073794 A CA 3073794A CA 3073794 A1 CA3073794 A1 CA 3073794A1
Authority
CA
Canada
Prior art keywords
compound according
mmol
mixture
heteroaryl
lcms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3073794A
Other languages
English (en)
French (fr)
Inventor
Benjamin Joseph Morrow
Richard Charles Foitzik
Michelle Ang Camerino
Helen Rachel Lagiakos
Scott Raymond Walker
Ylva Elisabet Bergman Bozikis
Graeme Irvine Stevenson
Anthony Nicholas Cuzzupe
Paul Anthony Stupple
Original Assignee
CTXT Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTXT Pty Ltd filed Critical CTXT Pty Ltd
Publication of CA3073794A1 publication Critical patent/CA3073794A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3073794A 2017-08-31 2018-08-31 Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family Abandoned CA3073794A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1713962.7 2017-08-31
GBGB1713962.7A GB201713962D0 (en) 2017-08-31 2017-08-31 Compounds
PCT/EP2018/073431 WO2019043139A1 (en) 2017-08-31 2018-08-31 FUSED [1,2,4] THIADIAZINE DERIVATIVES AS KAT INHIBITORS OF THE MYST FAMILY

Publications (1)

Publication Number Publication Date
CA3073794A1 true CA3073794A1 (en) 2019-03-07

Family

ID=60050736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073794A Abandoned CA3073794A1 (en) 2017-08-31 2018-08-31 Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family

Country Status (6)

Country Link
US (1) US20210380548A1 (enExample)
EP (1) EP3676266A1 (enExample)
JP (1) JP6975860B2 (enExample)
CA (1) CA3073794A1 (enExample)
GB (1) GB201713962D0 (enExample)
WO (1) WO2019043139A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028851B (zh) * 2019-06-03 2023-05-02 鲁南制药集团股份有限公司 一种帕瑞昔布钠中间体化合物
CN112028850B (zh) * 2019-06-03 2023-05-02 鲁南制药集团股份有限公司 一种帕瑞昔布钠的中间体化合物
WO2021030278A1 (en) * 2019-08-12 2021-02-18 Aligos Therapeutics, Inc. Bicyclic compounds
PT4181920T (pt) 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
EP4385989A4 (en) 2021-08-10 2024-12-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. SULFONAMIDE DERIVATIVE, MANUFACTURING PROCESS THEREOF AND MEDICAL USE THEREOF
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのkat6阻害剤を含む投与レジメン
CN120569381A (zh) 2023-02-10 2025-08-29 江苏恒瑞医药股份有限公司 一种磺酰胺衍生物结晶形式及其制备方法
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
WO2026133163A1 (en) 2024-12-19 2026-06-25 Pfizer Inc. Film coated solid dosage forms for management of dysgeusia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7179598A (en) * 1996-11-13 1998-06-03 Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
DE102005055355A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
GB201510019D0 (en) * 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds

Also Published As

Publication number Publication date
US20210380548A1 (en) 2021-12-09
WO2019043139A1 (en) 2019-03-07
JP6975860B2 (ja) 2021-12-01
GB201713962D0 (en) 2017-10-18
EP3676266A1 (en) 2020-07-08
JP2020531593A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
JP7692095B2 (ja) 化合物
JP6975860B2 (ja) Mystファミリーのkat阻害剤として作用する縮合[1,2,4]チアジアジン誘導体
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
EP3189048B1 (en) Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
AU2017226004B2 (en) Inhibitors of WDR5 protein-protein binding
AU2005260056B2 (en) Fused heterocyclic kinase inhibitors
US10494376B2 (en) Tetrahydroisoquinoline derived PRMT5-inhibitors
JP2016509048A (ja) アスパラギンメチル転移酵素の阻害剤としての2−(ヘテロ)アリールベンゾイミダゾール及びイミダゾピリジン誘導体
EP3423437A1 (en) Inhibitors of wdr5 protein-protein binding
WO2020002587A1 (en) Compounds
MX2012005518A (es) Derivados de pirazol amina triciclica.
JP2019001715A (ja) 三環性化合物
RU2838187C2 (ru) Соединения
WO2026015873A1 (en) Stat6 inhibitors and uses thereof
HK40041637A (en) Compounds
HK40041637B (en) Compounds
OA19881A (en) Compounds.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240228